Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estradiol supplementation modulates growth hormone (GH) secretory-burst waveform and recombinant human insulin-like growth factor-I-enforced suppression of endogenously driven GH release in postmenopausal women.
Veldhuis JD, Anderson SM, Kok P, Iranmanesh A, Frystyk J, Ørskov H, Keenan DM. Veldhuis JD, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2004 Mar;89(3):1312-8. doi: 10.1210/jc.2003-031482. J Clin Endocrinol Metab. 2004. PMID: 15001627 Clinical Trial.
Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive.
Veldhuis JD, Anderson SM, Patrie JT, Bowers CY. Veldhuis JD, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2004 Jan;89(1):121-7. doi: 10.1210/jc.2003-031291. J Clin Endocrinol Metab. 2004. PMID: 14715838 Clinical Trial.
Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
Evans WS, Anderson SM, Hull LT, Azimi PP, Bowers CY, Veldhuis JD. Evans WS, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2001 Feb;86(2):700-12. doi: 10.1210/jcem.86.2.7195. J Clin Endocrinol Metab. 2001. PMID: 11158034
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Veldhuis JD, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10. doi: 10.1210/jcem.86.7.7656. J Clin Endocrinol Metab. 2001. PMID: 11443205 Clinical Trial.
491 results